Galli Eugenio, Di Blasi Roberta, Pansini Ilaria, Cristinelli Caterina, Bommier Come, De Bernardis Ilenia, Corrente Alessandro, Viscovo Marcello, Montini Luca, Chiusolo Patrizia, Hohaus Stefan, Sorà Federica, Thieblemont Catherine, Sica Simona
Department of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Hemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.
Br J Haematol. 2025 Jun 23;207(2):642-7. doi: 10.1111/bjh.20222.
We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
我们将三种主要的合并症评分系统——累积疾病评分量表（CIRS）、造血细胞移植合并症指数（HCT-CI）和Severe4——应用于379例接受嵌合抗原受体T细胞（CAR-T）疗法治疗的大B细胞淋巴瘤（LBCL）患者队列。根据所使用的评分，7%至34%的患者被确定为合并症负担较高。然而，高合并症负担并未对CAR-T治疗的耐受性产生负面影响，包括细胞因子释放综合征（CRS）的发生率或血液学毒性。合并症负担低和高的患者之间，托珠单抗和皮质类固醇的使用情况以及非复发死亡率的累积发生率相当。
Cochrane Database Syst Rev. 2021-9-13
Transplant Cell Ther. 2024-11
Transplant Cell Ther. 2024-10
Hematology. 2025-12
Front Pharmacol. 2022-6-23
Zotero 插件